REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today ...
BERKELEY, Calif.--(BUSINESS WIRE)-- Bolt Projects Holdings, Inc. (BSLK), a developer of biomaterials for the beauty and personal care industry, announced preliminary results for the third quarter of ...
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results